SHIPPEO
23.3.2022 11:05:05 CET | Business Wire | Press release
UNILIN , a Belgian manufacturer of flooring, panels and insulation products for the home, has chosen Shippeo , a global leader and European specialist in real-time transportation visibility, to boost service and savings.
Headquartered in Belgium, UNILIN owns 15 powerful brands (including the Quickstep flooring brand) and distributes its products in over 23 countries throughout Europe. The company operates eight key loading sites, consisting of plants, warehouses and a cross dock, and makes over 100,000 deliveries per year to specialised DIY and building supplies retailers via a network of 20 carrier partners.
A lack of visibility of external transport quality, lead times and proof of delivery led UNILIN to look for a solution that would help with supply chain optimisation and the streamlining of processes, thereby improving customer service and enabling the company to stay competitive in its market.
By implementing Shippeo’s real-time transportation visibility solution to collect location data for all deliveries, UNILIN was able to proactively inform customers about potential delays. Shippeo’s advanced ability to track Less-than-Truckload (LTL) was critical, as LTL is UNILIN’s main and most complex transportation method. Shippeo’s solution has been specifically engineered to overcome tracking challenges associated with LTL by using advanced integrations with carriers’ Transportation Management Systems (TMS) and highly accurate geofencing techniques. The live location data captured, along with automatically generated proofs of delivery, is accessible to users on the Shippeo platform portal. Delivery status information provided by Shippeo will also be made available to UNILIN customers via their own customer portal.
Following the success of the first business use case for real-time transportation visibility, UNILIN is now exploring taking advantage of Shippeo’s mobile application for more granular visibility of own fleet shipments thanks to its parcel scanning capabilities.
Shippeo’s Dennis van Bodegom, Director Northern Europe, is thrilled to be working with UNILIN: “Our organisations both share a strong commitment to excellence in service, and I’m sure Shippeo’s real-time visibility and predictive capabilities will lead to an optimised and proactive supply chain, for the benefit of UNILIN as well as their customers.”
Geert van Damme, Transport & Distribution Manager at UNILIN, said: “I did some market studies and a lot of companies came up with ideas. But the only one who could convince me to do a proof of concept was Shippeo. The ability to automatically provide our customers with real-time tracking for all our LTL deliveries is a game changer. The level of data and insight we now have access to also brings much more clarity around our delivery performance.”
About Shippeo (https://www.shippeo.com
)
LinkedIn, Facebook, Twitter
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries.
About Unilin (https://www.unilin.com
)
Unilin Group is a global reference for interior design and building. The company engineers, manufactures and markets laminate flooring, luxury vinyl tiles, sheet vinyl, engineered parquet, carpet tiles, broadloom carpet, raw and decorative panels, industrial floors, wall and roof systems and insulation boards. Unilin employs 7.500 people at 105 locations all over the globe, 30 of which are production sites. In 2020, Unilin achieved a turnover of €2.21 billion. Customers and partners know the company as Unilin, IVC or Godfrey Hirst, or through one of its brands, such as Quick-Step, Moduleo, Utherm, Pergo, Evola, Xtratherm or ClicWall. Unilin Group is proudly part of Mohawk Industries, the world's largest flooring company with a turnover of $ 10 billion and 41.600 employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005915/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
